mayo clinic glp-1 SPECIAL EPISODE! Beyond Ozempic: The Boom Mayo Clinic Study: Hormone Therapy

For GLP1 RA initiators, 84.8% added metformin, 13.0% added SGLT2 inhibitors, and 2.2% added insulin, with no additions of DPP4 inhibitors or sulfonylureas

Importantly, initiation of GLP-1RA may decrease levothyroxine dose requirements in patients with hypothyroidism through weight loss, enhance levothyroxine absorption due to delayed gastrointestinal (GI) transit, and have direct effects on the hypothalamic-pituitary-thyroid axis [2329], potentially increasing the risk of thyroid hormone over-replacement (i.e., iatrogenic hyperthyroidism)

While opinions vary, patterns emerge over time, helping prospective players set realistic expectations

The Xultophy DUAL Phase 3 clinical trials showed combination therapy leads to greater HbA1c decrease and weight loss compared to insulin monotherapy [170]

PMID: 16410542